Tag Archives: hiv

December, 2015

  • 18 December

    GSK to Pay up to $1.5 Billion for Next Generation of HIV Treatments

    GlaxoSmithKline plc (LSE: GSK) today announced that its global HIV business, ViiV Healthcare, has reached two separate agreements with Bristol-Myers Squibb, to acquire its late-stage HIV R&D assets; and to acquire Bristol-Myers Squibb’s portfolio of preclinical and discovery stage HIV research assets. Under the terms agreed in the two transactions, …

November, 2015

  • 24 November

    HIV Treatment Choices Expand

    More than 1.2 million Americans live with HIV infection and one in eight has not yet been diagnosed, according to the Centers for Disease Control and Prevention. Despite public health initiatives, each year approximately 50,000 more Americans are infected with this virus. There is now a new medication available to …

  • 10 November

    Guided by Fibrosis Stage

    When to start treatment for hepatitis C can be a hotly debated topic, with sicker patients generally moved to the front of the line. However, the question remains: “how can we identify who are the ‘sicker patients’?” An effective way to identify which hepatitis C patients should get the most …

  • 5 November

    FDA Approves Gilead’s HIV Drug Cocktail

    FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ:GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1 infection. Genvoya is the first TAF-based regimen to receive FDA approval. Genvoya is …

  • 4 November

    ViiV Announces Positive Mid-Stage Results for its HIV Therapy

    London, UK, 3 November 2015 – ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today announced that the Phase IIb study LATTE 2 (NCT02120352) met its primary endpoint at 32 weeks. These results show that the investigational, long acting, injectable formulations of …

October, 2015

  • 23 October

    Gilead Announces Positive Results from its Late-Stage HIV Study

    BARCELONA, Spain–(BUSINESS WIRE)–Oct. 22, 2015– Gilead Sciences, Inc. (NASDAQ:GILD) today announced 96-week results from two Phase 3 studies (Studies 104 and 111) evaluating its investigational once-daily single tablet regimen (STR), Genvoya® (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg or E/C/F/TAF), for the treatment …

July, 2015

May, 2015

April, 2015

  • 8 April

    New Antibody Shows Promise in Treating HIV

    An experimental antibody therapy has shown promise in suppressing HIV infection, bringing optimism to the HIV field and suggesting new strategies for fighting or even preventing HIV. Rockefeller University researchers have found that an experimental therapy, part of a new generation of so-called broadly neutralizing antibodies, can dramatically reduce the …

  • 6 April

    HIV-Infected Veterans Have Higher Rates of Medicare/Medicaid Enrollment

    A substantial proportion of veterans are dually enrolled in the Veterans Affairs (VA) healthcare system as well as Medicare and/or Medicaid, which leads to care received inside and outside of the VA. However, the use of non-VA healthcare among this population can lead to fragmented, inefficient, and lower quality of …